Ignite Creation Date:
2025-12-25 @ 2:40 AM
Ignite Modification Date:
2026-03-11 @ 7:35 AM
Study NCT ID:
NCT02227433
Status:
COMPLETED
Last Update Posted:
2020-12-22
First Post:
2014-08-11
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease.
Sponsor:
Fondazione Italiana Linfomi - ETS
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
FIL_BVHD01
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None